Czech and Slovak Ophthalmology 471 Original article Retinopathy of Prematurity Part II Prepiaková Zuzana https://orcid.org/0009-0004-4596-2657 Tomčíková Dana https://orcid.org/0000-0002-9285-7066 Kostolná Barbora https://orcid.org/0009-0003-6780-0539 Gerinec Anton 22 4 2014 2 2

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies that potentially leads to blindness. Authors describe revised indications for the treatment of ROP, standard treatment – peripheral retinal ablation by laser photocoagulation and the cryotherapy using off label treatment-intravitreal anti-VEGF injection.

 retinopathy of prematurity indications laser photocoagulation cryotherapy intravitreal anti-VEGF therapy References Autrata, R., Krejãírová, I., Šenková, K.,et al.: Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol, 22(5); 2012: 687–94. Autrata, R., Šenková, K., Holousová, M, et al.: Retinopatie nedonošených a možnosti chirurgické léčby. Folia Stra- bol Neuroophthalmol, X; 2009: 40–45. Banach, M.J., Ferrone, P.J., Trese, M.T.: A comparison of dense versus less dense diod laser photocoagulati- on patterns for threshold retinopathy of prematurity. Ophthalmology, 107; 2000: 324–328. Banach, M.J.,Berinstein, D.M.: Laser therapy for retinopathy of prematurity. Current Opinion in Ophthalmology, 12; 2001: 164–170. Castellanos, M. A. M., Schwartz, S., García-Aguirre, G., et al.: Short-term Outcome After Intravitreal Ranibizumab Injections for the Treatment of Retinopathy of Prematurity. Br J Ophthalmol. 97(7); 2013: 816–819. Cook, Anne, White, S., Batterbury, M., Clark, D.: Ocular growth and refractive error development in premature infants without retinopathy of prematurity. Invest Ophthalmol Vis Sci, 44(3), 2003: 953-960. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2 year outcomestructure and function. Arch Ophthalmol. 111;1993: 339–44. Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 106; 1988: 471–9. Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity: Ophthalmological outcomes at 10 years. Arch Ophthalmol, 119; 2001: 1110–1118. Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol, 121(12), 2003: 1684–1694. Fisher, S.K.: Cellular effects of detachment on the neural retina and retinal pigment epithelium. In: Ryan,S.J.: Retina(ed 2), St Louis, Mosby, 1994, s. 2035–2061. Fung, A.E., Rosenfeld, P.J., Reichel, E.: The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol, 90(11), 2006: 1344–1349. Gilbert, C., Foster, A.: Childhood blindness in the context of VISION 2020: the right to sight. Bulletin of the World Health Organization, 79(3); 2001: 227–232. Gonzales, C. R., Boshra, J., Schwartz, S. D.: 25-Gauge pars plicata vitrectomy for stage 4 and 5 retinopathy of prematurity. Retina, 26(7); 2006: S42–S46. Gonzales, V.H., Giuliari, G.P., Banda, R.M et al.: Confluent Laser Photocoagulation for the Treatment of Retinopathy of Prematurity, J Pediatr Ophthalmol Strabismus, 47(2), 2010: 81–85. Honda, S., Hirabayashi, H., Tsukahara, Y., Negi, A.: Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 246(7); 2008: 1061–3. Christiansen, S.P., Bradford, J.D.: Cataract in infants treated with argon laser photocoagulation for threshold retinopathy of prematurity, Am J Ophthalmol, 119(2); 1995: 175–80. Lakhanpal, R. R., Fortun, J. A., Chan- -Kai, B., et al.: Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity. Retina, 26(7); 2006: 736–740. Lalwani, G.A., Berrocal, A.M., Murray, T.G. et al.: Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity, Retina, 28; 2008: 13–18. Lashkari, K., Hirose, T., Yazdany, J., et al.: Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol, 156(4); 2000: 1337– 1344. Law, J.C., Recchia, F.M., Morrison, D.G. et al.: Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS, 14(1); 2010: 6–10. Lee, J.Y., Chae, J.B., Yang, S.J. et al.: Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol, 248(9); 2010: 1257–1262. Kong, L., Mintz-Hintzer, A.H.: Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth FactorTherapy for Retinopathy of Prematurity: A Morfologic Study. Arch. Ophthalmol, 126(8); 2008: 1161–1163. Mintz-Hittner, H.A., Kennedy, K.A., Chuang, A.Z.: BEAT-ROP cooperative group: efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med, 364(7); 2011: 603–615. Mintz-Hittner, H.A., Kuffel, R.R.: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina, 28(6); 2008: 831–838. Mota, Á., Carneiro, Á., Breda, J., et al.: Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity. Case Rep Ophthalmol, 3(1); 2012: 136–141. Mutlu, F.M., Sarici, S.U.: Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol, 6(2); 2013: 228–236. Paysse, E.A., Hussein, M.A., Miller, A.M. et al.: Pulsed mode versus near continous mode delivery of diode laser photocoagulation for high– risk retinopathy of prematurity. JAAPOS, 11; 2007: 388–392. Pieh, C., Agostini, H., Buschbeck, C. et al.: VEGF-A,VEGF-1, VEGFR-2 und Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol, 92(5); 2008: 689–693. Repka, M.X.: Ophthalmological problems of the premature infant. Ment Retard Dev Disabil Res Rev, 8; 2002: 249-57. Roohipoor, R., Ghasemi, H., Ghassemi, F. et al.: Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol, 249(9); 2011: 1295–1301. Roohipoor, R., Karkhaneh, R., Riazi- -Esfahani, M. et al.: Surgical management in advanced stages of retinopathy of prematurity; our experience. Journal of ophthalmic & vision research, 4(3); 2009: 185–190. Sato, T., Wada, K., Arahori, H. et al.: Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol, 153(2); 2012: 327–333. Sears, J. E., Sonnie, C.: Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol, 143(5); 2007: 810–813. Shah, P. K., Narendran, V., Kalpana, N. et al.: Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity. Eye, 23(1); 2009: 176–180. Shima, C., Sakaguchi, H., Gomi, F. et al.: Complications in patient after intravitreal injection of bevacizumab. Acta Ophthalmol, 86(4); 2008: 372–376. Smith, L. E.: Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci, 49(12); 2008: 5177–5182. Tomšíková, D., Prepiaková, Z., Kostolná, B. et al.: Prínos konfluujúcej (paint) – diódlaserkoagulácie v liečbe retinopatie nezrelých detí. Čes a Slov Oftal, 67; 2011: 115–118. Tawansy, K. A., Samuel, M. A.: Retinopathy of prematurity: practical surgical management in the new millennium. Tech Ophthalmol, 2; 2004: 60–67. Tsukahara, Y., Honda, S., Imai, H. et al.: Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol, 144(1); 2007: 139–141.